As the Q2 earnings season comes to a close, it’s time to take stock of this quarter’s best and worst performers in the senior health, home health & hospice industry, including BrightSpring Health Services (NASDAQ: BTSG) and its peers.
The senior health, home care, and hospice care industries provide essential services to aging populations and patients with chronic or terminal conditions. These companies benefit from stable, recurring revenue driven by relationships with patients and families that can extend many months or even years. However, the labor-intensive nature of the business makes it vulnerable to rising labor costs and staffing shortages, while profitability is constrained by reimbursement rates from Medicare, Medicaid, and private insurers. Looking ahead, the industry is positioned for tailwinds from an aging population, increasing chronic disease prevalence, and a growing preference for personalized in-home care. Advancements in remote monitoring and telehealth are expected to enhance efficiency and care delivery. However, headwinds such as labor shortages, wage inflation, and regulatory uncertainty around reimbursement could pose challenges. Investments in digitization and technology-driven care will be critical for long-term success.
The 7 senior health, home health & hospice stocks we track reported a mixed Q2. As a group, revenues missed analysts’ consensus estimates by 0.5%.
Amidst this news, share prices of the companies have had a rough stretch. On average, they are down 9% since the latest earnings results.
Best Q2: BrightSpring Health Services (NASDAQ: BTSG)
Founded in 1974, BrightSpring Health Services (NASDAQ: BTSG) offers home health care, hospice, neuro-rehabilitation, and pharmacy services.
BrightSpring Health Services reported revenues of $3.87 billion, up 23% year on year. This print exceeded analysts’ expectations by 5.9%. Overall, it was a very strong quarter for the company with a beat of analysts’ EPS estimates and full-year revenue guidance slightly topping analysts’ expectations.
"We are pleased with the Company’s second quarter results that reflect our quality focus, service level performance, and dedication to the patients we serve," said Jon Rousseau, Chairman, President, and Chief Executive Officer of BrightSpring.
BrightSpring Health Services achieved the biggest analyst estimate beat of the whole group. Investor expectations, however, were likely higher than Wall Street’s published projections, leaving some wishing for even better results (analysts’ consensus estimates are those published by big banks and advisory firms, not the investors who make buy and sell decisions). The stock is down 17.4% since reporting and currently trades at $60.18.
Chemed (NYSE: CHE)
With a unique business model combining end-of-life care and household services, Chemed (NYSE: CHE) operates two distinct businesses: VITAS, which provides hospice care for terminally ill patients, and Roto-Rooter, which offers plumbing and water restoration services.
Chemed reported revenues of $673.3 million, up 8.8% year on year, outperforming analysts’ expectations by 1.2%. The business had a very strong quarter with an impressive beat of analysts’ full-year EPS guidance estimates and a beat of analysts’ EPS estimates.
The market seems content with the results as the stock is up 4.4% since reporting. It currently trades at $540.55.
Is now the time to buy Chemed? Access our full analysis of the earnings results here, it’s free.
Weakest Q2: AdaptHealth (NASDAQ: AHCO)
With a network of approximately 680 locations serving patients across all 50 states, AdaptHealth (NASDAQ: AHCO) provides home medical equipment, supplies, and related services to patients with chronic conditions like sleep apnea, diabetes, and respiratory disorders.
AdaptHealth reported revenues of $740.3 million, up 12.7% year on year, falling short of analysts’ expectations by 12.6%. It was a disappointing quarter as it posted full-year revenue and EBITDA guidance missing analysts’ expectations significantly.
AdaptHealth delivered the weakest performance against analyst estimates and weakest full-year guidance update among its peers. As expected, the stock is down 48.3% since the results and currently trades at $5.60.
Read our full analysis of AdaptHealth’s results here.
Option Care Health (NASDAQ: OPCH)
With a nationwide network of 177 locations serving 43 states and a team of over 4,500 clinicians, Option Care Health (NASDAQ: OPCH) is the largest independent provider of home and alternate site infusion services, delivering medications and clinical support to patients across the United States.
Option Care Health reported revenues of $1.44 billion, up 1.9% year on year. This number topped analysts’ expectations by 1.6%. It was a strong quarter as it also put up an impressive beat of analysts’ full-year EPS guidance estimates and a beat of analysts’ EPS estimates.
The stock is up 5.3% since reporting and currently trades at $23.68.
Read our full, actionable report on Option Care Health here, it’s free.
Brookdale (NYSE: BKD)
With a network of over 650 communities serving approximately 59,000 residents across 41 states, Brookdale Senior Living (NYSE: BKD) operates senior living communities across the United States, offering independent living, assisted living, memory care, and continuing care retirement communities.
Brookdale reported revenues of $718.6 million, down 11.6% year on year. This print missed analysts’ expectations by 2.3%. Taking a step back, it was a mixed quarter as it also produced a beat of analysts’ EPS estimates but full-year EBITDA guidance meeting analysts’ expectations.
Brookdale had the slowest revenue growth in the group. The stock is down 11% since reporting and currently trades at $12.19.
Read our full, actionable report on Brookdale here, it’s free.
Market Update
Over the past year, investors have been forced to repeatedly answer the same question: what is the market’s biggest risk? The answer has changed several times, and each shift has reshaped market leadership.
Late in 2025 and early 2026, artificial intelligence became the market’s primary uncertainty. Investors questioned whether AI would erode software pricing power and weaken competitive moats as AI made it easier to replicate once-differentiated products.
By the spring, technology took a back seat to geopolitics. The U.S. conflict with Iran briefly became the market’s dominant narrative, raising concerns about oil prices, inflation, and global growth. But as energy markets remained orderly and fears of a prolonged supply disruption faded, investors quickly turned their focus back to fundamentals.
Want to invest in winners with rock-solid fundamentals? Check out our Strong Momentum Stocks and add them to your watchlist. These companies are poised for growth regardless of the political or macroeconomic climate.
